Surgical treatment for recurrent cholangiocarcinoma: a single-center series
PurposeThe present study aims to assess the results obtained after surgical treatment of cholangiocarcinoma (CC) recurrences.MethodsWe carried out a single-center retrospective study, including all patients with recurrence of CC. The primary outcome was patient survival after surgical treatment comp...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-04-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1169133/full |
| _version_ | 1797844912715071488 |
|---|---|
| author | Laura Fernández Mikel Gastaca Mikel Gastaca Eva Alonso Mikel Prieto Mikel Prieto Patricia Ruiz Alberto Ventoso Ibone Palomares Arkaitz Perfecto Andrés Valdivieso Andrés Valdivieso |
| author_facet | Laura Fernández Mikel Gastaca Mikel Gastaca Eva Alonso Mikel Prieto Mikel Prieto Patricia Ruiz Alberto Ventoso Ibone Palomares Arkaitz Perfecto Andrés Valdivieso Andrés Valdivieso |
| author_sort | Laura Fernández |
| collection | DOAJ |
| description | PurposeThe present study aims to assess the results obtained after surgical treatment of cholangiocarcinoma (CC) recurrences.MethodsWe carried out a single-center retrospective study, including all patients with recurrence of CC. The primary outcome was patient survival after surgical treatment compared with chemotherapy or best supportive care. A multivariate analysis of variables affecting mortality after CC recurrence was performed.ResultsEighteen patients were indicated surgery to treat CC recurrence. Severe postoperative complication rate was 27.8% with a 30-day mortality rate of 16.7%. Median survival after surgery was 15 months (range 0-50) with 1- and 3-year patient survival rates of 55.6% and 16.6%, respectively. Patient survival after surgery or CHT alone, was significantly better than receiving supportive care (p< 0.001). We found no significant difference in survival when comparing CHT alone and surgical treatment (p=0.113). Time to recurrence of <1 year, adjuvant CHT after resection of the primary tumor and undergoing surgery or CHT alone versus best supportive care were independent factors affecting mortality after CC recurrence in the multivariate analysis.ConclusionSurgery or CHT alone improved patient survival after CC recurrence compared to best supportive care. Surgical treatment did not improve patient survival compared to CHT alone. |
| first_indexed | 2024-04-09T17:30:02Z |
| format | Article |
| id | doaj.art-24881df41bda422fabef7ad689da4b84 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-09T17:30:02Z |
| publishDate | 2023-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-24881df41bda422fabef7ad689da4b842023-04-18T06:31:28ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-04-011310.3389/fonc.2023.11691331169133Surgical treatment for recurrent cholangiocarcinoma: a single-center seriesLaura Fernández0Mikel Gastaca1Mikel Gastaca2Eva Alonso3Mikel Prieto4Mikel Prieto5Patricia Ruiz6Alberto Ventoso7Ibone Palomares8Arkaitz Perfecto9Andrés Valdivieso10Andrés Valdivieso11General Surgery Department, Hospital de Urduliz, Urduliz, SpainHepatobiliary Surgery and Liver Transplantation Unit, Biocruces Bizkaia Health Research Institute, Hospital Universitario Cruces, Bilbao, SpainFacultad de Medicina y Odontología, Universidad del País Vasco/ Euskal Herriko Unibertsitatea (UPV/EHU), Leioa, SpainGeneral Surgery Department, Hospital Universitario Cruces, Bilbao, SpainHepatobiliary Surgery and Liver Transplantation Unit, Biocruces Bizkaia Health Research Institute, Hospital Universitario Cruces, Bilbao, SpainFacultad de Medicina y Odontología, Universidad del País Vasco/ Euskal Herriko Unibertsitatea (UPV/EHU), Leioa, SpainHepatobiliary Surgery and Liver Transplantation Unit, Biocruces Bizkaia Health Research Institute, Hospital Universitario Cruces, Bilbao, SpainHepatobiliary Surgery and Liver Transplantation Unit, Biocruces Bizkaia Health Research Institute, Hospital Universitario Cruces, Bilbao, SpainHepatobiliary Surgery and Liver Transplantation Unit, Biocruces Bizkaia Health Research Institute, Hospital Universitario Cruces, Bilbao, SpainHepatobiliary Surgery and Liver Transplantation Unit, Biocruces Bizkaia Health Research Institute, Hospital Universitario Cruces, Bilbao, SpainHepatobiliary Surgery and Liver Transplantation Unit, Biocruces Bizkaia Health Research Institute, Hospital Universitario Cruces, Bilbao, SpainFacultad de Medicina y Odontología, Universidad del País Vasco/ Euskal Herriko Unibertsitatea (UPV/EHU), Leioa, SpainPurposeThe present study aims to assess the results obtained after surgical treatment of cholangiocarcinoma (CC) recurrences.MethodsWe carried out a single-center retrospective study, including all patients with recurrence of CC. The primary outcome was patient survival after surgical treatment compared with chemotherapy or best supportive care. A multivariate analysis of variables affecting mortality after CC recurrence was performed.ResultsEighteen patients were indicated surgery to treat CC recurrence. Severe postoperative complication rate was 27.8% with a 30-day mortality rate of 16.7%. Median survival after surgery was 15 months (range 0-50) with 1- and 3-year patient survival rates of 55.6% and 16.6%, respectively. Patient survival after surgery or CHT alone, was significantly better than receiving supportive care (p< 0.001). We found no significant difference in survival when comparing CHT alone and surgical treatment (p=0.113). Time to recurrence of <1 year, adjuvant CHT after resection of the primary tumor and undergoing surgery or CHT alone versus best supportive care were independent factors affecting mortality after CC recurrence in the multivariate analysis.ConclusionSurgery or CHT alone improved patient survival after CC recurrence compared to best supportive care. Surgical treatment did not improve patient survival compared to CHT alone.https://www.frontiersin.org/articles/10.3389/fonc.2023.1169133/fullcholangiocarcinomarecurrencesurgical treatmentoutcomeschemotherapy |
| spellingShingle | Laura Fernández Mikel Gastaca Mikel Gastaca Eva Alonso Mikel Prieto Mikel Prieto Patricia Ruiz Alberto Ventoso Ibone Palomares Arkaitz Perfecto Andrés Valdivieso Andrés Valdivieso Surgical treatment for recurrent cholangiocarcinoma: a single-center series Frontiers in Oncology cholangiocarcinoma recurrence surgical treatment outcomes chemotherapy |
| title | Surgical treatment for recurrent cholangiocarcinoma: a single-center series |
| title_full | Surgical treatment for recurrent cholangiocarcinoma: a single-center series |
| title_fullStr | Surgical treatment for recurrent cholangiocarcinoma: a single-center series |
| title_full_unstemmed | Surgical treatment for recurrent cholangiocarcinoma: a single-center series |
| title_short | Surgical treatment for recurrent cholangiocarcinoma: a single-center series |
| title_sort | surgical treatment for recurrent cholangiocarcinoma a single center series |
| topic | cholangiocarcinoma recurrence surgical treatment outcomes chemotherapy |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1169133/full |
| work_keys_str_mv | AT laurafernandez surgicaltreatmentforrecurrentcholangiocarcinomaasinglecenterseries AT mikelgastaca surgicaltreatmentforrecurrentcholangiocarcinomaasinglecenterseries AT mikelgastaca surgicaltreatmentforrecurrentcholangiocarcinomaasinglecenterseries AT evaalonso surgicaltreatmentforrecurrentcholangiocarcinomaasinglecenterseries AT mikelprieto surgicaltreatmentforrecurrentcholangiocarcinomaasinglecenterseries AT mikelprieto surgicaltreatmentforrecurrentcholangiocarcinomaasinglecenterseries AT patriciaruiz surgicaltreatmentforrecurrentcholangiocarcinomaasinglecenterseries AT albertoventoso surgicaltreatmentforrecurrentcholangiocarcinomaasinglecenterseries AT ibonepalomares surgicaltreatmentforrecurrentcholangiocarcinomaasinglecenterseries AT arkaitzperfecto surgicaltreatmentforrecurrentcholangiocarcinomaasinglecenterseries AT andresvaldivieso surgicaltreatmentforrecurrentcholangiocarcinomaasinglecenterseries AT andresvaldivieso surgicaltreatmentforrecurrentcholangiocarcinomaasinglecenterseries |